Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy

(2017) Alanna J Church et al.   MODERN PATHOLOGY

Identification of NTRK fusions in pediatric mesenchymal tumors

(2017) Dean Pavlick et al.   PEDIATRIC BLOOD & CANCER

Congenital mesoblastic nephroma 50 years after its recognition: A narrative review

(2017) S. L. Gooskens et al.   PEDIATRIC BLOOD & CANCER

ETV6 -NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study

(2017) Christian Vokuhl et al.   PEDIATRIC BLOOD & CANCER

Recurrent and metastatic congenital mesoblastic nephroma: where does the evidence stand?

(2017) Susan Jehangir et al.   PEDIATRIC SURGERY INTERNATIONAL

Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups

(2007) Marry M. van den Heuvel-Eibrink et al.   PEDIATRIC BLOOD & CANCER